Marseille, France – (BUSINESS WIRE) – Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (” Born ” or ” society Today, we will hold a telephone conference on Tuesday, May 10, 2022 at 2:00 pm (Central European Summer Time) / 8:00 am (Central European Summer Time) to discuss the first quarter 2022 performance and portfolio progress. Announced that.
The meeting is moderated by:
Mondher Mahjoubi, Chairman of the Executive Committee
Joyson Karakunnel, Executive Vice President, Chief Medical Officer
Executive Vice President of Product Strategy and Business Development, Janice Morel
Frederick Lombard, Senior Vice President, Chief Financial Officer
A live stream of events is available at the following link:
Participants can also join the meeting by calling the following numbers:
France: 0805 620 704
USA: 1844200 6205/1646904 5544
United Kingdom: 44208 0682 558/44808189648
Others: +1 929 526 1599
Access code: 051477
This information is also available in the Investors section of the Innate website at www.innate-pharma.com. Presentation replays will be archived on the Innate website for 90 days after the event.
About Innate Pharma:
Innate Pharma SA is a clinical stage biotechnology company specializing in immuno-oncology, working to improve cancer treatment through innovative therapeutic antibodies that utilize the immune system.
Innate Pharma’s extensive antibody portfolio includes several potentially first-in-class candidates in the clinical and preclinical stages of cancer with high medical need.
Innate Pharma is a pioneer in understanding NK cell biology and has developed expertise in tumor microenvironment and tumor antigens, and antibody engineering. With its innovative approach, it builds a diverse and unique portfolio, forming partnerships with major biopharmaceutical companies such as Bristol Myers Squibb, Novo Nordisk A / S and Sanofi, as well as multi-product partnerships with AstraZeneca. I was able to.
Based in Marseille and a subsidiary in Rockville, Maryland, Innate Pharma is listed on Euronext Paris and Nasdaq in the United States.
Find InnatePharma at www.innate-pharma.com.
Euronext: IPH Nasdaq: IPHA
Forward-looking information and risk factor disclaimers:
This press release contains forward-looking statements, including the implications of the Private Securities Litigation Reform Act of 1995. The purpose is to identify the use of certain terms such as “believe”, “potential”, “expect”, “will” and other similar expressions regarding future prospects. We believe our forecasts are based on reasonable assumptions, but these forward-looking statements may be questioned by certain risks and uncertainties and are not forecasts. It can produce significantly different results. These risks and uncertainties include the uncertainties inherent in research and development in particular. This includes funding for safety, ongoing or planned clinical and pre-clinical trial progress and results, regulatory review and approval of our product candidates, our commercial efforts, and development. Our ability to continue, and the overall impact of the COVID-19 pandemic on our healthcare system and activities, financial condition and our performance. The “Risk Factors” section of the Universal Registration document submitted to Autorité des marchés lenders for additional considerations regarding risks and uncertainties that may make a difference in the company’s actual results, financial condition, performance and success. Please refer to. (AMF), Innate Pharma (www.innate-pharma.com) and AMF (www.amf-france.org) websites, and documents and public reports submitted to the US Securities and Exchange Commission (SEC). (Available at), Annual Report on Form 20-F for the fiscal year ended December 31, 2020, and subsequent documents and reports, submitted to the AMF or SEC, or other. Includes reports published by us in the manner.
This press release and the information contained therein do not constitute an offer to sell or subscribe to Innate Pharma shares, or solicit purchase or subscription orders in any country.
For additional information, please contact:
Investor and press relations
Phone: +33 (0) 4 84 90 32 88
like that. : +33 (0) 9 81 87 46 72